The Centers for Medicare and Medicaid Services (CMS) released new details this week to help stakeholders navigate the Inflation Reduction [...] …
Blog Posts
Maxor, a leading integrated pharmacy services and 340B solutions provider first established nearly 100 years ago in a small Texas [...] …
Three major drugmakers recently announced refunds for 340B covered entities that purchased certain drugs in 2022 and 2023 following recalculations [...] …

SPONSORED CONTENT

TIP: Align charge capture and 340B strategy to unlock long-term sustainability.
In today’s margin-pressured environment, 340B savings
In the final hour of Oklahoma’s 2025 legislative session, as the clock neared 11 p.m. on May 29, state legislators [...] …
A key health policy staffer for U.S. Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Bill Cassidy (R-La.) recently [...] …
For the third straight time in 2025, a federal audit has found a drug manufacturer overcharged covered entities for 340B [...] …
Two drugmakers recently added new medications to the list of drugs subject to their respective 340B contract pharmacy restrictions—one of [...] …
A recent drug-industry-funded study attributes the 340B program’s recent growth to increased utilization—not rising drug prices. The May 21 study, [...] …
Novartis and Bristol Myers Squibb (BMS) are asking a federal appeals court to expedite their challenge to a recent ruling [...] …